In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …

Purpose: Integration of evolutionary dynamics into systemic therapy for metastatic cancers
can prolong tumor control compared with standard maximum tolerated dose (MTD) …

The development of chemotherapeutic resistance resulting in tumor relapse is largely the
consequence of the mechanism of competitive release of pre-existing resistant tumor cells …

Abiraterone treats metastatic castrate-resistant prostate cancer by inhibiting CYP17A, an
enzyme for testosterone auto-production. With standard dosing, evolution of resistance with …

Background: Abiraterone acetate is an effective treatment for metastatic castrate-resistant
prostate cancer (mCRPC), but evolution of resistance inevitably leads to progression. We …

In the absence of curative therapies, treatment of metastatic castrate-resistant prostate
cancer (mCRPC) using currently available drugs can be improved by integrating …

Adaptive therapy seeks to exploit intratumoral competition to avoid, or at least delay, the
emergence of therapy resistance in cancer. Motivated by promising results in prostate …

Intermittent androgen deprivation therapy (IADT) is an attractive treatment for biochemically
recurrent prostate cancer (PCa), whereby cycling treatment on and off can reduce …

Abiraterone acetate (AA) has been proven effective for metastatic castration-resistant
prostate cancer (mCRPC), and it has been proposed that adaptive AA may reduce toxicity …

Background Adaptive therapy aims to tackle cancer drug resistance by leveraging resource
competition between drug-sensitive and resistant cells. Here, we present a theoretical study …